Wedbush raised the firm’s price target on ARS Pharmaceuticals to $13 from $5 and keeps an Outperform rating on the shares following financial results and key business updates. The firm says market opportunity is intact per post-CRL survey.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRY:
- ARS Pharmaceuticals reports Q3 EPS (16c), consensus (18c)
- ARS Pharmaceuticals presents clinical data on neffy for allergic reactions
- ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- ARS Pharmaceuticals announces scheduling of Type A meeting with FDA for neffy
- ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)